Cite
Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization.
MLA
Berger, M. G., et al. “Preferential Sensitivity of Hematopoietic (HPs) and Mesenchymal (MPs) Progenitors to Fludarabine Suggests Impaired Bone Marrow Niche and HP Mobilization.” Leukemia (08876924), vol. 22, no. 11, Nov. 2008, pp. 2131–34. EBSCOhost, https://doi.org/10.1038/leu.2008.167.
APA
Berger, M. G., Berger, J., Richard, C., Jeanpierre, S., Nicolini, F. E., Tournilhac, O., Michallet, M., & Satta, V. M. (2008). Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia (08876924), 22(11), 2131–2134. https://doi.org/10.1038/leu.2008.167
Chicago
Berger, M. G., J. Berger, C. Richard, S. Jeanpierre, F. E. Nicolini, O. Tournilhac, M. Michallet, and V. M. Satta. 2008. “Preferential Sensitivity of Hematopoietic (HPs) and Mesenchymal (MPs) Progenitors to Fludarabine Suggests Impaired Bone Marrow Niche and HP Mobilization.” Leukemia (08876924) 22 (11): 2131–34. doi:10.1038/leu.2008.167.